ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Vitamin D Deficiency Linked to Neurological Diseases; Also Raises Risk of Asthma Attacks, and More

7 Best Foods You Can Eat

Study: Doubling saturated fat in the diet does not increase saturated fat in blood

The Gut Microbiome and the Brain

Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed

CoQ10 supplementation reduces statin-related muscle pain in randomized trial

Controlling obesity with potato extract

Plant used in traditional Chinese medicine may treat metabolic diseases and obesity

Natural Gut Viruses Join Bacterial “Cousins” in Maintaining Health and Fighting Infections

Proton pump inhibitors decrease diversity in gut microbiome, increase risk for complications

 
Print Page
Email Article

Results of Switching Fibromyalgia Patients from Cymbalta to Savella

  [ 5 votes ]   [ Discuss This Article ]
www.ProHealth.com • May 14, 2013


Editor's comment:  There are currently three drugs that have received FDA approval for the treatment of fibromyalgia (brand names: Lyrica, Cymbalta and Savella).  Each one has roughly a 30% success rate for improving FM symptoms.  Therefore, when one medication is not helping a patient, it is not unusual for the treating physician to switch the patient to one of the other approved drugs.  The purpose of this study was to assess the results of switching fibromyalgia patients who were not being helped by duloxotine (Cymbalta) to milnacipran (Savella).  The researchers sought to answer two primary questions: (1) Would patients experience any improvements in pain or other symptoms after switching medications? (2) Can patients be switched from one medication to the other without first tapering down the dosage of the first medication?

Note: You may read the full text of this article free HERE.

Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study

By Lucinda Bateman, et al.

Abstract:

BACKGROUND:
The purpose of this study was to evaluate the safety, tolerability, and efficacy of milnacipran following a direct switch from duloxetine in fibromyalgia patients experiencing inadequate clinical response to duloxetine after receiving treatment for 6 weeks or longer.

METHODS: This exploratory study included 107 patients with fibromyalgia who had been treated with duloxetine 60 mg/day for at least 4 weeks prior to enrollment. Following a 2-week open-label period on duloxetine, patients who had visual analog scale pain scores ≥ 40 and were dissatisfied with current treatment were randomized 4:1 to milnacipran 100 mg/day (n = 86) or placebo (n = 21) for 10 weeks of double-blind treatment. The small placebo group was included solely to blind the study and minimize expectation bias among patients and investigators, and there was no preplanned statistical comparison between treatment groups.

The primary efficacy parameter was the percentage of patients rating themselves as "much improved" or "very much improved" on the Patient Global Impression of Change (PGIC) at the final visit. Other efficacy parameters included changes in one-week recall visual analog scale pain, Fibromyalgia Impact Questionnaire Revised (FIQR), and Multiple Ability Self-Report Questionnaire (MASQ).

RESULTS: Of patients switched to milnacipran, 32.9% were classified as PGIC responders, and they also demonstrated improvement in visual analog scale pain, FIQR total, and MASQ total scores (mean changes from baseline were -12.3, -7.77, and -2.39, respectively).

Nausea and dizziness were the most common treatment-emergent adverse events in patients switched to milnacipran, reported in 21% and 15%, respectively, of patients in this group.

CONCLUSION:
Results from this exploratory study suggest that switching from duloxetine to milnacipran may be beneficial in some patients with fibromyalgia who have an inadequate response to duloxetine. Further research investigating the efficacy and safety of switching fibromyalgia therapies is warranted.

Source: Journal of Pain Research, April 26, 2013. By Lucinda Bateman, Robert H Palmer, Joel M Trugman, and Yuhua Lin. Fatigue Consultation Clinic, Salt Lake City, UT.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Protecting Our Eyes Against Time-Induced Damage Protecting Our Eyes Against Time-Induced Damage

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing